文献速递衰弱、肌少症与跌倒老年综合评估老年慢病共病管理

胱抑素C与肌酐估算肾小球滤过率差值同肌肉量与衰弱的关系

Difference between kidney function by cystatin C versus creatinine and association with muscle mass and frailty.
PubMed 文献 · J Am Geriatr Soc · 2024-05-31

该研究为MrOS队列第14年的横断面分析,纳入490名年龄≥65岁男性,评估eGFRDiff(eGFRCys - eGFRCreat)与氘代肌酸稀释法测定的全身肌肉量及衰弱表型的关系。结果显示eGFRDiff每增加1个标准差,肌肉量平均高1.4 kg(p<0.0001),较高eGFRDiff与较低衰弱风险相关(OR=0.63,95%CI 0.45-0.89),但额外校正肌肉量后该关联减弱且不显著(OR=0.85,95%CI 0.58-1.24)。

要点

  • eGFRDiff每增1个标准差,全身肌肉量平均高1.4 kg(p<0.0001)。
  • 较高eGFRDiff与较低衰弱风险相关(OR=0.63,95%CI 0.45-0.89)。
  • 校正肌肉量后eGFRDiff与衰弱的关联减弱且不显著(OR=0.85,95%CI 0.58-1.24)。

核心结论

  • 在晚年男性中,较高的eGFRDiff与较低的衰弱风险相关,全身肌肉量可解释部分关联。

研究设计与样本

  • 多中心MrOS研究第14年(第4次访视)的横断面分析,纳入490名基线年龄≥65岁的男性。

主要发现

  • eGFRDiff每增加1个标准差,氘代肌酸稀释法测定的肌肉量平均高1.4 kg(p<0.0001,完全校正模型)。
  • 较高eGFRDiff与较低衰弱风险相关(OR=0.63,95%CI 0.45-0.89)。
  • 额外校正肌肉量后,eGFRDiff与衰弱的关联减弱且不显著(OR=0.85,95%CI 0.58-1.24)。

关键数值与推荐

  • 暴露为eGFRDiff(eGFRCys - eGFRCreat),采用CKD-EPI 2012/2021方程计算。
  • 主要结局为氘代肌酸稀释法测定的全身肌肉量(kg)。
  • 次要结局为衰弱表型:衰弱前期为1或2项标准,衰弱为≥3项标准,标准包括体重下降、无力、步速慢、体力活动、精力差。

临床怎么用

  • 在老年男性中解读eGFRDiff时需考虑肌肉量对肌酐估算的影响。
  • eGFRDiff与衰弱的关联部分由肌肉量解释,提示肌肉量评估可能有助于衰弱风险分层。

局限性

  • 横断面设计无法推断因果关系。
  • 仅纳入男性,结果不能外推至女性。
  • 样本量490人,来自原始队列5994人。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: A higher difference in estimated glomerular filtration rate by cystatin C versus creatinine (eGFRDiff = eGFRCys - eGFRCreat) is associated with decreased frailty risk. Since eGFRCreat is influenced by muscle more than eGFRCys, muscle mass may explain this association. Previous work could not account for this when considering regional muscle measures by imaging. Deuterated creatine (D3Cr) dilution measures whole body muscle mass (kilograms). We aimed to determine whether eGFRDiff is associated with D3Cr muscle mass and whether muscle mass explains the association between eGFRDiff and frailty. METHODS: Cross-sectional analysis within the multicenter MrOS Study at Year 14 (visit 4). 490 men of the original cohort of 5994 MrOS participants (aged ≥65 at enrollment) were included. Exposure was eGFRDiff (= eGFRCys - eGFRCreat), calculated using CKD-EPI equations 2012/2021. Primary outcome was D3Cr muscle mass. Secondary outcome was phenotypic pre-frailty (one or two criteria) and frailty (≥three criteria) including the following: weight loss, weakness, slow gait, physical activity, poor energy. The association of eGFRDiff with D3Cr muscle mass was examined by linear regression, that with prefrailty / frailty by multinomial logistic regression. RESULTS: Mean ± SD age was 84 ± 4 years, eGFRCreat 68 ± 16, eGFRCys 52 ± 16, eGFRDiff -15 ± 12 mL/min/1.73 m2 and D3Cr muscle mass 24 ± 4 kg. For each SD increment in eGFRDiff, D3Cr muscle mass was 1.4 kg higher on average, p < 0.0001 (fully adjusted). Higher eGFRDiff was associated with lower odds of frailty (OR = 0.63 95% CI [0.45;0.89]), but this was partially attenuated and insignificant after additionally adjusting for D3Cr muscle mass (OR = 0.85 95% CI [0.58; 1.24]). CONCLUSIONS: Higher eGFRDiff is associated with lower odds of frailty among late-life men. D3Cr muscle mass accounts for some of this association. This suggests that non-GFR determinants of creatinine and cystatin C, such as muscle mass, play a role in explaining the association of eGFRDiff with frailty. Future studies are needed to confirm.

来源:J Am Geriatr Soc,查看原文。版权归原作者所有。

引用

  1. Yuan JH, Rifkin DE, Ginsberg C, et al. Difference between kidney function by cystatin C versus creatinine and association with muscle mass and frailty. J Am Geriatr Soc. 2024. PMID: 38819605. doi:10.1111/jgs.19014

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。